All In Biotech

Drug Trial Radar · NCT05710198

Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma

A Phase III Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 873 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

873

Actual

Start

Dec 11, 2023

Primary completion

Jul 1, 2029

Study completion Jul 1, 2029

Sponsor

Lead sponsor
Omikron Italia S.r.l.Industry
Sponsor type
Industry
Collaborators
OPIS Spain
First posted
Feb 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of citicoline eye drops 2% in reducing visual field deterioration in patients with progressing OAG treated according to best clinical practice. Secondary objectives are assessing the effect of citicoline eye drops 2% on changes in structural parameters measured by Spectral Domain Optical Coherence Tomography (SD-OCT) and evaluating the safety of citicoline eye drops 2%

Conditions

  • Glaucoma, Open-Angle

Interventions

  • Citicoline eye drops 2%Drug

    Eye drops containing Citicoline 2%

  • PlaceboDrug

    Eye drops containing placebo matching product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression of visual field damageTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Presidio Ospedale San Paolo

    Milan, MI, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.